Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex
- PMID: 12695507
- DOI: 10.1074/jbc.M302895200
Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex
Abstract
Covalent antithrombin-heparin (ATH) complexes, formed spontaneously between antithrombin (AT) and unfractionated standard heparin (H), have a potent ability to catalyze the inhibition of factor Xa (or thrombin) by added AT. Although approximately 30% of ATH molecules contain two AT-binding sites on their heparin chains, the secondary site does not solely account for the increased activity of ATH. We studied the possibility that all pentasaccharide AT-binding sequences in ATH may catalyze factor Xa inhibition. Chromatography of ATH on Sepharose-AT resulted in >80% binding of the load. Similar chromatographies of non-covalent AT + H mixtures lead to a lack of binding for AT and fractionation of H into unbound (separate from AT) or bound material. Gradient elution of ATH from Sepharose-AT gave 2 peaks, a peak containing higher affinity material that had greater anti-factor Xa catalytic activity (708 units/mg heparin) compared with the peak containing lower affinity material (112 units/mg). Sepharose-AT chromatography of the ATH component with short heparin chains (<or=12 monosaccharides) resulted in active unbound (40%) and bound fractions (190 and 560 units/mg, respectively). Factor Xa-ATH or thrombin-ATH inhibitor complexes gave chromatograms on Sepharose-AT with more unbound material compared with that of free ATH. Also, ATH did not bind to Sepharose-heparin, and the intrinsic fluorescence due to activation of AT in ATH by its heparin chain was reversed at higher [NaCl] than that required to dissociate non-covalent AT.H complexes. Thus, exogenous AT can compete with the AT moiety of ATH for binding to the covalently linked heparin chain, leading to catalytic inhibition of factor Xa or thrombin. These data may suggest that access to pentasaccharide units in non-covalent AT.H complexes by free AT may be facile.
Similar articles
-
Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex.J Biol Chem. 1998 Dec 25;273(52):34730-6. doi: 10.1074/jbc.273.52.34730. J Biol Chem. 1998. PMID: 9856996
-
Inhibition of fibrin-bound thrombin by a covalent antithrombin-heparin complex.J Biochem. 2002 Aug;132(2):167-76. doi: 10.1093/oxfordjournals.jbchem.a003206. J Biochem. 2002. PMID: 12153711
-
Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.J Biol Chem. 1992 Jun 25;267(18):12528-38. J Biol Chem. 1992. PMID: 1618758
-
Mechanism of heparin action.Baillieres Clin Haematol. 1990 Jul;3(3):483-504. doi: 10.1016/s0950-3536(05)80015-0. Baillieres Clin Haematol. 1990. PMID: 2176902 Review.
-
Covalent antithrombin-heparin complexes.Thromb Res. 2007;120(2):151-60. doi: 10.1016/j.thromres.2006.08.003. Epub 2006 Sep 14. Thromb Res. 2007. PMID: 16978685 Review.
Cited by
-
Effect of endothelium on the anticoagulant activity of a covalent antithrombin-heparin complex.Sci Rep. 2024 Sep 27;14(1):22335. doi: 10.1038/s41598-024-72458-0. Sci Rep. 2024. PMID: 39333740 Free PMC article.
-
Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution?-A narrative review.J BioX Res. 2022 Sep;5(3):97-103. doi: 10.1097/JBR.0000000000000125. Epub 2022 Aug 29. J BioX Res. 2022. PMID: 36212029 Free PMC article. Review.
-
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.J Biochem. 2013 Jan;153(1):103-10. doi: 10.1093/jb/mvs129. Epub 2012 Oct 24. J Biochem. 2013. PMID: 23100269 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical